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Abstract 
 
Alzheimer's disease is associated with the accumulation within the brain of amyloid-β (Aβ) peptides that damage 
synapses and affect memory acquisition. This process can be modelled by observing the effects of Aβ on synapses in 
cultured neurons. The addition of picomolar concentrations of soluble Aβ derived from brain extracts triggered the 
loss of synaptic proteins including synaptophysin, synapsin-1 and cysteine string protein from cultured neurons. 
Glimepiride, a sulphonylurea used for the treatment of diabetes, protected neurons against synapse damage induced 
by Aβ.  The protective effects of glimepiride were multi-faceted. Glimepiride treatment was associated with altered 
synaptic membranes: a reduction in synaptic cholesterol following the loss of specific glycosylphosphatidylinositol 
(GPI)-anchored proteins including the cellular prion protein (PrPC) that acts as a receptor for Aβ42, increased synaptic 
gangliosides and altered cell signalling. More specifically, glimepiride reduced the Aβ-induced increase in cholesterol 
and the Aβ-induced activation of cytoplasmic phospholipase A2 (cPLA2) in synapses that occurred within cholesterol-
dense membrane rafts. Aβ42 binding to glimepiride-treated neurons was not targeted to membrane rafts and less Aβ42 
accumulated within synapses. These studies indicate that glimepiride modified the membrane micro-environments in 
which Aβ-induced signalling leads to synapse damage. In addition, soluble PrPC, released from neurons by 
glimepiride, neutralised Aβ-induced synapse damage. Such observations raise the possibility that glimepiride may 
reduce synapse damage and hence delay the progression of cognitive decline in Alzheimer’s disease. 
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1. Introduction  
 
Alzheimer's disease (AD), a genetically heterogeneous disease that is the most common form of dementia, is a complex 
neurological disorder characterized by a progressive dementia (Selkoe, 2002; Tanzi, 2005). The amyloid hypothesis 
of AD pathogenesis maintains that the main event leading to AD is the production of toxic amyloid-β (Aβ) peptides 
derived from proteolytic cleavage of the amyloid precursor protein by β and γ secretases (De Strooper et al., 2010; 
Hardy and Selkoe, 2002). The cognitive decline in AD patients coincides with increasing concentrations of Aβ in the 
brain (Naslund et al., 2000) which leads to the subsequent disruption of neuronal processes, abnormal phosphorylation 
of tau and synapse damage. Some of the events that lead to neurodegeneration in AD can be examined by incubating 
cultured neurons with Aβ peptides.  
 
In this study we measured concentrations of synaptic proteins in cultured primary cortical neurons incubated with Aβ 
preparations to study the molecular mechanisms involved in synapse degeneration. Since soluble Aβ oligomers that 
can diffuse throughout the brain are regarded as highly potent neurotoxins (Haass and Selkoe, 2007; Lambert et al., 
1998) soluble forms of “natural Aβ” were isolated from brain extracts. The addition of soluble Aβ oligomers reduced 
the amounts of synaptophysin, synapsin-1, cysteine string protein (CSP) and vesicle-associated membrane protein 
(VAMP)-1 in cultured neurons indicative of synapse damage (Bate et al., 2010) thus providing a reliable tissue culture 
model of the synapse damage that is observed in AD. The biological effects of these Aβ oligomers occur at picomolar 
concentrations, similar to those in extracts from human brain or cerebrospinal fluid (Mc Donald et al., 2010; McLean 
et al., 1999; Wang et al., 1999). 
 
Numerous biochemical, epidemiological, pharmacological and genetic studies demonstrated that cholesterol is a risk 
factor for the development of AD (Jick et al., 2000; Li et al., 2007; Puglielli et al., 2003). The requirement of 
cholesterol for the formation of specific membrane micro-domains called lipid rafts (Rajendran and Simons, 2005) is 
thought to be is a critical factor affecting AD pathogenesis. The observations that Aβ42 accumulates within rafts  
(Kawarabayashi et al., 2004; Oshima et al., 2001) and that rafts are essential for the formation of signalling platforms  
(Mayor and Rao, 2004) suggests that Aβ42 triggers the events that lead to neurotoxicity from within rafts. This 
hypothesis is supported by the observation that cholesterol depletion protected neurons against Aβ-induced 
neurodegeneration (Bate and Williams, 2007; Wang et al., 2001). However, cholesterol synthesis inhibitors are 
Abbreviations 
Alzheimer’s disease (AD), amyloid-β (Aβ), cellular prion protein (PrPC), chloromercuriphenylsulphonate (p-
CMPS), cytoplasmic phospholipase A2 (cPLA2), cysteine-string protein (CSP), detergent-resistant memnbranes 
(DRM)s, di-methyl sulphoxide (DMSO), glycosylphosphatidylinositol (GPI), high performance thin-layer 
chromatography (HPTLC) , phosphatidylinositol (PI), phospholipase A2-Activating Peptide (PLAP), phospholipase 
C (PLC), polyacrylamide gel electrophoresis (PAGE), prostaglandin (PG), vesicle-associated membrane protein 
(VAMP)-1.  
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regarded as crude pharmacological tools as cholesterol depletion also affects many other neuronal processes including 
the sensitivity of neurotransmitter receptors (Allen et al., 2007). The observation that rafts exist as multiple 
heterogeneous subsets containing different proteins and with different functions (Pike, 2004) raised the possibility that 
compounds that alter the function of specific rafts involved in Aβ-induced neurodegeneration could be discovered. 
The factors that affect the formation and function of rafts are inadequately understood. Rafts contain many proteins 
attached to cell membranes via glycosylphosphatidylinositol (GPI) anchors (Legler et al., 2005; Mayor and Riezman, 
2004). As GPI anchors promote the formation of rafts (Brown and London, 2000), drugs that affect GPI anchors may 
consequently affect the composition and function of rafts.   
 
Glimepiride, a sulphonylurea used to treat diabetes, activates an endogenous GPI-phospholipase C (GPI-PLC) 
(Movahedi and Hooper, 1997) leading to the release of GPI-anchored proteins including the cellular prion protein 
(PrPC) that has been identified as a receptor that mediates Aβ-induced synapse damage (Lauren et al., 2009). 
Consequently glimepiride was reported to reduce membrane cholesterol (Bate et al., 2009) and affect the distribution 
of raft-resident proteins (Müller et al., 2005). Here we report that glimepiride protected neurons against Aβ-induced 
synapse damage. It did not affect the incorporation of Aβ42 into neurons, rather it reduced the Aβ-induced changes in 
cell membranes and the activation of cytoplasmic phospholipase A2 (cPLA2) in synapses. 
 
2. Materials and Methods 
 
2.1. Primary neuronal cultures - Cortical neurons were prepared as described (Lesuisse and Martin, 2002). Neurons 
were plated (2 x 105 cells/well) in 48 well plates pre-coated with poly-L-lysine) in Ham’s F12 containing 5% foetal 
calf serum for 2 hours. Cultures were shaken (600 r.p.m for 5 minutes) and non-adherent cells removed by 2 washes 
in PBS. Neurons were grown in neurobasal medium containing B27 components supplemented with nerve growth 
factor (5 nM) for 10 days. Immunohistochemistry showed that the cells were greater than 90% neurofilament positive. 
Neurons were subsequently pre-treated with test compounds including glimepiride, glipizide, p-
chloromercuriphenylsulphonate (p-CMPS) or 0.2 units/ml phosphatidylinositol (PI)-PLC derived from Bacillus 
cereus (all from Sigma) for 1 hour before the addition of test samples including Aβ or Phospholipase A2-Activating 
Peptide (PLAP) (Bachem) for 24 hours. All experiments were performed in accordance with European regulations 
(European Community Council Directive, 1986, 56/609/EEC). 
2.2. Isolation of synaptosomes - Synaptosomes were prepared from cultured neurons on a discontinuous Percoll 
gradient as described (Thais et al., 2006; Westmark et al., 2011). Neurons were homogenized at 4°C in 1 ml of SED 
solution (0.32 M sucrose, 50 mM Tris-HCl, pH 7.2, 1 mM EDTA, and 1 mM dithiothreitol) and centrifuged at 1000 
× g for 10 minutes. The supernatant was transferred to a 4-step gradient of 3, 7, 15, and 23% Percoll in SED solution 
and centrifuged at 16,000 × g for 30 minutes at 4oC. Synaptosomes were collected from the interface of the 15% and 
23% Percoll steps and washed in PBS before use. Isolated synaptosomes were pre-treated for 1 hour and incubated 
with peptides for 1 hour. 
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2.3. Cell/synaptosome extracts - Treated neurons/synaptosomes were washed 3 times with PBS and homogenised in 
a buffer containing 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.2% SDS, mixed protease inhibitors (4-
(2-aminoethyl) benzenesulfonyl fluoride, Aprotinin, Leupeptin, Bestain, Pepstatin A and E-46) and a phosphatase 
inhibitor cocktail (PP1, PP2A, microcystin LR, cantharidin and p-bromotetramisole) (Sigma) at 106 cells/ml. Nuclei 
and cell debris were removed by centrifugation (300 x g for 5 minutes).  
 
2.4. Isolation of detergent-resistant membranes (DRMs)/membrane rafts - Membrane rafts were isolated by their 
insolubility in non-ionic detergents. Briefly, samples were homogenised in an ice-cold buffer containing 1% Triton 
X-100, 10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 10 mM EDTA and mixed protease inhibitors and nuclei and large 
fragments were removed by centrifugation (300 x g for 5 minutes at 4oC). The post nuclear supernatant was incubated 
on ice (4oC) for 1 hour and centrifuged (16,000 x g for 30 minutes at 4oC). The supernatant was reserved as the 
detergent soluble membrane (DSM) while the insoluble pellet was homogenised in an extraction buffer containing 10 
mM Tris-HCL, pH 7.4, 150 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS 
and mixed protease inhibitors at 106 cells/ml, centrifuged (10 minutes at 16,000 x g) and the soluble material was 
reserved as the DRM fraction.  
 
2.5. Western Blotting - Samples were mixed with Laemmli buffer, heated to 95oC for 5 minutes and proteins were 
separated by electrophoresis on 15 or 12% polyacrylamide gels (PAGE). Proteins were transferred onto a Hybond-P 
PVDF membrane by semi-dry blotting. Membranes were blocked using 10% milk powder; PrP was detected by 
incubation with mAb ICSM18, synaptophysin with MAB368 (Abcam), CSP with rabbit polyclonal anti-CSP ((sc-
33154) Santa Cruz), VAMP-1 with mAb 4H302 (Abcam), synapsin-1 with a rabbit polyclonal antibody (515200, 
Invitrogen), caveolin with rabbit polyclonal antibodies (Upstate) and Thy-1 with a rat mAb (Abcam). Bound 
antibodies were visualised using a combination of biotinylated anti-mouse/rat/rabbit IgG (Sigma), extravidin-
peroxidase and enhanced chemiluminescence.  
 
2.6. Isolation of PrPC and Thy-1 – PrPC and Thy-1 were prepared from neurons as described (Bate and Williams, 
2012). Briefly, cells were homogenised in a buffer containing 10 mM Tris-HCl pH 7.4, 100 mM NaCl, 10 mM EDTA, 
0.5 % Nonidet P-40, 0.5 % sodium deoxycholate and mixed protease inhibitors (as above). Cell debris was removed 
by centrifugation and soluble membrane preparations were passed over affinity columns loaded with mAbs to PrPC 
(ICSM35) or anti-Thy-1 (Abcam). PrPC and Thy-1 was eluted using glycine-HCl at pH 2.7, neutralised with 1 M Tris 
pH 7.4, desalted and concentrated. Soluble forms of PrPC and Thy-1 were collected in the supernatants of neurons 
treated with 5 µM glimepiride. Supernatants were concentrated and desalted by centrifugation with a 3 kDa filter. 
Native and soluble proteins were isolated via reverse phase chromatography on C18 columns (Waters). For bioassays 
samples were solubilised in culture medium by sonication. The amounts of PrPC in samples were measured by ELISA 
as described (Bate and Williams, 2011) and the amounts of Thy-1 by a bicinchoninic acid protein assay (Pierce). PrPC 
preparations were analysed via high performance thin-layer chromatography (HPTLC) on silica gel 80 plates 
(Whatman). Samples were applied and developed using a mixture of choloroform/methanol/water (4/4/1 - v/v/v).  
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Plates were soaked in 0.1 % polyisobutyl methacrylate in hexane, dried, and blocked with 5 % milk powder. They 
were probed with 1 µg /ml of mAb ICSM18, washed with PBS-Tween, and incubated with goat anti–mouse IgG 
conjugated to peroxidase (Sigma) for 1 hour. The bound antibody was visualised using chemiluminescence.  
 
2.7. Treatment of glimepiride-treated supernatants - Supernatants from glimepiride-treated neurons were 
incubated with 0.1 μg/ml mAb ICSM18 (reactive with PrPC) and incubated at 4oC on rollers for 1 hour. Protein G 
microbeads (Sigma) were added (10 µl/ml) for 30 minutes and protein G-antibody complexes were removed by 
centrifugation (16,000 x g for 10 minutes). Mock-depletions involved incubating supernatants with 0.1 μg/ml of an 
isotype control followed by protein G microbeads under the same conditions as above. Depleted media was filtered 
before further use. 
 
2.8. Synaptophysin ELISA - The amounts of synaptophysin in neurons were measured by ELISA as described (Bate 
et al., 2010). Maxisorb immunoplates (Nunc) were coated with a mouse monoclonal antibody (mAb) to synaptophysin 
MAB368 (Millipore). Samples were applied and bound synaptophysin was detected using rabbit polyclonal anti-
synaptophysin (Abcam) followed by a biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and 1 mg/ml 4-
nitrophenol phosphate solution. Absorbance was measured on a microplate reader at 405 nm. Samples were expressed 
as “units synaptophysin” where 100 units was defined as the amount of synaptophysin in 106 control neurons.  
2.9. CSP ELISA – Maxisorb immunoplates were coated with a mAb to CSP ((sc-136468) Santa Cruz) and blocked 
with 5% milk powder. Samples were added and bound CSP was detected using rabbit polyclonal anti-CSP ((sc-33154) 
Santa Cruz) followed by a biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenol 
phosphate solution. Absorbance was measured at 405 nm. Samples were expressed as “units CSP” where 100 units 
was the amount of CSP in 106 control cells.  
2.10. Cholesterol - The concentrations of cholesterol in samples were measured using the Amplex Red cholesterol 
assay kit (Invitrogen), according to the manufacturer’s instructions. Briefly, cholesterol is oxidised by cholesterol 
oxidase to yield hydrogen peroxide and ketones. The hydrogen peroxide reacts with 10-acetyl-3, 7-
dihydroxyphenoxazine (Amplex Red reagent) to produce highly fluorescent resorufin, which is measured by excitation 
at 550 nm and emission detection at 590 nm.  
2.11. cPLA2 ELISA - Maxisorb immunoplates were coated with 0.5 µg/ml of mAb anti-cPLA2 (clone CH-7, Upstate) 
and blocked with 5% milk powder in PBS-tween. Samples were incubated for 1 hour and the amount of cPLA2 was 
detected using a goat polyclonal anti-cPLA2 (Santa-Cruz Biotech) followed by biotinylated anti-goat IgG, extravidin-
alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate solution. Absorbance was measured at 405 nm and the 
amount of cPLA2 was calculated. The amount of cPLA2 protein was expressed in units (100 units = amount of cPLA2 
in control preparations).  
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2.12. Activated cPLA2 ELISA - The activation of cPLA2 is accompanied by phosphorylation of the 505 serine residue 
which creates a unique epitope and can be measured by ELISA as described (Bate et al., 2010). Maxisorb 
immunoplates were coated with 0.5 µg/ml of mouse mAb anti-cPLA2, clone CH-7 (Upstate) and blocked. Samples 
were incubated for 1 hour and the amount of activated cPLA2 was detected using rabbit polyclonal anti-phospho-
cPLA2 (Cell Signalling Technology) followed by biotinylated anti-rabbit IgG (Sigma), extravidin-alkaline 
phosphatase and 1mg/ml 4-nitrophenyl phosphate solution. Results were expressed as “units activated cPLA2” with 
100 units defined as the amount of activated cPLA2 in in control preparations. 
2.13. Brain extracts – The temporal lobe from a 78 year old female with a clinical, and pathologically-confirmed, 
diagnosis of Alzheimer’s disease, was supplied by Asterand, an international supplier of human tissue. Soluble extracts 
were prepared using methodology as previously described (Shankar et al., 2008). Briefly, brain tissue was cut into 
pieces of approximately 100 mg and added to 2 ml tubes containing lysing matrix D beads (Q-Bio). Neurobasal 
medium containing B27 components was added so that there was the equivalent of 100 mg brain tissue/ml. The tubes 
were shaken for 10 minutes (Disruptor genie, Scientific Instruments) to disrupt tissue. This process was performed 3 
times and tubes were centrifuged at 16,000 x g for 10 minutes to remove cell debris. Soluble material was prepared 
by passage through a 30 kDa filter. The amounts of Aβ in each soluble extract were measured by ELISA (see below) 
and the supernatant aliquoted and stored at -80oC. For immunoblot analysis, extracts were concentrated, mixed with 
an equal volume of 0.5% NP-40, 5 mM CHAPS, 50 mM Tris, pH 7.4 and separated by PAGE. Proteins were 
transferred onto a PVDF membrane by semi-dry blotting and blocked using 10% milk powder. Aβ was detected by 
incubation with mAb 6E10 (Covance), biotinylated anti-mouse IgG, extravidin-peroxidase and enhanced 
chemiluminescence.  
2.14. Immunodepletions - Brain extracts were incubated with 0.1 μg/ml mAb 4G8 (reactive with amino acids 17-24 
of Aβ) and incubated at 4oC on rollers for 1 hour. Protein G microbeads (Sigma) were added (10 µl/ml) for 30 minutes 
and protein G-antibody complexes were removed by centrifugation (16,000 x g for 10 minutes). Mock-depletions 
involved incubating brain extracts with 0.1 μg/ml of an isotype control followed by protein G microbeads under the 
same conditions as above. Depleted media was filtered before further use. 
 
2.15. PrPC ELISA - The amount of PrPC in samples was determined by ELISA as described (Bate et al., 2010). 
Briefly, Maxisorb immunoplates were coated with mAb ICSM18 (D-Gen). Samples were added and bound PrP was 
detected with biotinylated mAb ICSM35 (D-Gen). Biotinylated mAb was detected using extravidin-alkaline 
phosphatase and 1 mg/ml 4-nitrophenyl phosphate solution. Absorbance was measured on a microplate reader at 405 
nm and the amount of PrP in samples was calculated by reference to a standard curve of recombinant murine PrP 
(Prionics).  
 
2.16. Aβ binding to PrPC – Maxisorb immunoplates were coated with PrPC or soluble PrPC and blocked by the 
addition of 5% milk powder. Samples were added for 1 hour and bound Aβ was detected by the addition of 10 nM 
biotinylated mAb 6E10 (epitope = 1-16) (Covance) followed by 0.5 μg/ml of extravidin-alkaline phosphatase and 1 
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mg/ml 4-nitrophenyl phosphate solution. Absorbance was measured on a microplate reader at 405 nm and the amount 
of Aβ calculated by reference to a standard curve of synthetic Aβ1-42 (Bachem).  
 
2.17. Gangliosides – Synaptosomes were solubilised in chloroform/methanol/water (1/4/5). Extracts (5 µl) were 
applied to silica gel 60 high performance thin layer chromatography (HPTLC) plates (Whatman) and developed using 
a mixture of choloroform/methanol/water (4/4/1 - v/v/v). Plates were soaked in 0.1 % poly(isobutyl methacrylate) in 
hexane, dried, and blocked with PBS containing 5 % milk powder. Sialic acid containing lectins were detected by the 
addition of 1 µg/ml biotinylated Sambucus nigra lectin (Vector Labs) followed by extravidin peroxidase and detected 
with chemiluminescence. To quantify the amount of gangliosides in synaptosomes samples were diluted in propanol 
(1 in 100), 50 µl was plated into Nunc Maxisorb immunoplates and left to dry overnight. Plates were blocked with a 
5% milk powder and gangliosides were detected by the addition of 1 µg/ml biotinylated Sambucus nigra lectin 
followed by extravidin alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate solution. Absorbance was measured 
on a microplate reader at 405 nm. 
 
 
2.18.  Sample preparation - To detach Aβ42 from cellular binding proteins that could occlude specific epitopes cell 
extracts (200 μl) were mixed with 500 μl of 70% formic acid and sonicated. A 50 μl aliquot was added to 450 μl of 1 
M Tris–HCl with protease inhibitors (as above) and sonicated before addition to ELISA. 
 
2.19.  Aβ42 ELISA – Nunc Maxisorb immunoplates were coated with mAb 4G8 (epitope 17-24) (Covance) in 
carbonate buffer overnight. Plates were blocked with 5% milk powder in PBS-Tween and samples were applied. The 
detection antibody was an Aβ42 selective rabbit mAb BA3-9 (Covance) followed by biotinylated anti-rabbit IgG 
(Sigma). Total Aβ was visualised by addition of 4-nitrophenyl phosphate solution. Absorbance was measured on a 
microplate reader at 405 nm and results were calculated by comparison to serial dilutions of synthetic Aβ42.  
 
2.20. Statistical Analysis - Comparison of treatment effects was carried out using Student’s t-tests, Error bars are 
standard deviation (SD) and significance was set at P<0.01. Correlations were analysed using SPSS. 
 
3. Results 
 
3.1. Aβ triggers synapse damage in cultured neurons - The amounts of synaptic proteins in neurons incubated with 
Aβ was studied in a tissue culture model of AD-related synapse damage. An immunoblot showed that the brain extracts 
contained a mixture of Aβ monomers, dimers and trimers that were removed by depletion with the Aβ-reactive mAb 
G48 (Figure 1A). The addition of brain extracts to cultured neurons caused the loss of synaptic proteins including 
synapsin-1, VAMP-1, CSP and synaptophysin from cultured neurons (Figure 1B). However, brain extracts did not 
affect the amounts of caveolin, nor did it significantly reduce cell viability as measured by the thiazolyl blue 
tetrazolium (MTT) method (09% cell survival ± 6 compared with 100% ± 5, n=12, P=0.04). In order to quantify 
synapse damage ELISA specific for synaptophysin and CSP were used. Brain extracts caused a dose-dependent 
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rduction in the amounts of both synaptophysin and CSP within neurons (Figures 1C & D). While brain extracts contain 
Aβ it was not clear whether it was Aβ that was responsible for the synapse damage in these neuronal cultures. 
Immunodepletion with mAb G48 reduced concentrations of both Aβ40 (4.9 nM ± 0.3 to 0.3 nM ± 0.3 nM) and Aβ42 
(1.2 nM ± 0.16 to 0.11 nM ± 0.1 nM) in brain extracts, whereas mock-depletion had no significant effect on either 
Aβ40 (4.9 nM ± 0.3 to 4.7 nM ± 0.3 nM) and Aβ42 (1.2 nM ± 0.16 to 1.1 nM ± 0.1 nM). The addition of brain extract 
that had been depleted of Aβ did not trigger the loss of synaptophysin of CSP from neurons indicating that the toxic 
entity was Aβ and consistent with the hypothesis that Aβ is a major neurotoxin in AD brains. Notably, the synapse 
damage was triggered by brain extract containing nanomolar/picomolar concentrations of Aβ42, concentrations similar 
to those observed in CSF (Mc Donald et al., 2010; McLean et al., 1999; Wang et al., 1999).  As Aβ42 is considered to 
be more neurotoxic than Aβ40 in all further studies the amount of brain extract added was standardized on the amount 
of Aβ42 it contained. 
 
3.2. Glimepiride reduced Aβ-induced synapse damage – Since the identification of compounds that protect neurons 
against Aβ-induced synapse damage is a rational strategy to treat AD the effects of glimepiride on neurons were 
studied. Glipizide, another sulphonylurea used to treat diabetes, was used as a control. Firstly we found that the 
addition of 5 µM glimepiride or glipizide alone did not alter the amounts of synaptophysin or CSP in neurons 
indicating that these drugs did not cause synapse damage. Next, pre-treatment with 5 µM glimepiride, but not glipizide, 
protected neurons against the Aβ-induced loss of synaptophysin or CSP (Figures 2A and B). The protective effect of 
glimepiride was dose-dependent (Figure 2C). To determine whether the continued presence of glimepiride was 
essential for its protective effects, neurons were treated with 5 μM glimepiride for 1 hour and then washed 3 times 
prior to the addition of Aβ for a further 24 hours. Neurons treated in this way remained partially resistant to Aβ (Figure 
2D). Glimepiride-treated neurons were not protected against all toxins; the loss of synaptophysin and CSP from 
neurons incubated with PLAP was not affected by pre-treatment with 5 μM glimepiride (Figures 2E & F). 
 
3.3. Digestion with PI-PLC protected neurons against Aβ-induced synapse damage – Some of the effects of 
glimepiride are mediated by activation an endogenous GPI-PLC (Müller et al., 1994). As this is an effect of glimepiride 
that was not shared by glipizide we hypothesised that activation of GPI-PLC was the key factor responsible for the 
protective effect of glimepiride. Two methods were used to test this hypothesis. Firstly, neurons treated with PI-PLC 
showed less synapse damage when incubated with Aβ than did control neurons (Figures 4A & B). Next, we sought to 
reverse the effect of glimepiride by the use of p-CMPS, an inhibitor of GPI-PLC (Stanton et al., 2002). The addition 
of 200 μM p-CMPS alone did not affect the synaptophysin content of neurons (97 units ± 8 compared to 100 ± 7, n=9, 
P=0.7) or affect synapse damage induced by Aβ. However, the addition of 200 μM p-CMPS reversed the protective 
effect of 5 µM glimepiride. Thus, the synaptophysin content of neurons incubated with Aβ was higher when pre-
treated with 5 µM glimepiride than when pre-treated with a combination of 5 µM glimepiride and 200 µM p-CMPS 
(Figures 3C & D). These results are consistent with the hypothesis that the activation of GPI-PLC was responsible for 
the neuroprotective effect of glimepiride.  
9 
 
Since the activation of GPI-PLC can release some GPI-anchored proteins from cells, the possibility that 
glimepiride affected cellular receptors for Aβ and hence the binding of Aβ42 to neurons was studied. Neurons treated 
with 5 µM glimepiride or digested with PI-PLC were incubated with 5 nM Aβ42 for 1 hour. There were no significant 
differences in the concentrations of Aβ42 found in neurons between control and glimepiride-treated neurons (4.68 nM 
Aβ42 ± 0.28 compared with 4.64 nM ± 0.27, n=9, P=0.81) or between control and PI-PLC digested neurons (4.68 nM 
Aβ42 ± 0.282 compared with 4.52 nM ± 0.25, n=9, P=0.26). 
 
3.4. Glimepiride reduced the expression of PrPC at synapses – The effects of glimepiride upon synapses were 
studied by isolating synaptosomes from neurons treated with glimepiride for 1 hour. The protein, synaptophysin and 
CSP content of synaptosomes from control and glimepiride-treated neurons were not significantly different. The 
cellular prion protein (PrPC), identified as a receptor for Aβ42 (Lauren et al., 2009), is attached to membranes via a GPI 
anchor (Stahl et al., 1987) and released by the addition of glimepiride (Bate et al., 2009). Treatment of neurons with 
glimepiride, but not glipizide, caused a dose-dependent reduction in the concentrations of PrPC in synaptosomes 
(Figure 4A). Treatment with glimepiride was selective; it did not affect the amounts of the GPI-anchored Thy-1, nor 
did affect the amounts of caveolin or VAMP-1 in synaptosomes (Figure 4B). The glimepiride-induced reduction in of 
PrPC in synaptosomes was reduced by the inclusion of 200 μM p-CMPS which increased the concentration of synaptic 
PrPC from 0.3 ± 0.2 nM to 1.78 ± 0.27 nM, n=9, P<0.05. When treated synaptosomes were analysed by HPTLC, 
glimepiride-treated synaptosomes were found to contain more gangliosides than control synaptosomes (Figure 4C). 
Glimepiride caused a dose-dependent increase in the ganglioside content of synapses; the amounts of gangliosides in 
synaptosomes showed a significant inverse correlation with concentrations of PrPC, Pearson’s coefficient=-0.801, 
P<0.01 (Figure 4D). 
Next, the effects of glimepiride on the binding of Aβ to synapses were tested using isolated synaptosomes. 
Pre-treatment with 5 µM glimepiride did not significantly alter the amounts of Aβ42 that bound to synaptosomes; there 
were no significant difference in the concentrations of Aβ42 in control and treated synaptosomes after incubation with 
1 nM Aβ42 (0.9 nM Aβ42 ± 0.07 compared with 0.89 nM ± 0.09, P=0.59, n=9). Such results indicate that PrPC is not 
the only receptor that can bind Aβ42 expressed at synapses. Since Aβ42 is found within cholesterol-dense rafts in brain 
and neuronal extracts (Kawarabayashi et al., 2004; Lee et al., 1998), the effect of glimepiride on the binding of Aβ42 
to rafts was examined. When synaptosomes were incubated for 1 hour with 1 nM Aβ42, most of the Aβ42 was found 
in rafts (DRMs). Pre-treatment of synaptosomes with 5 µM glimepiride resulted in a significant reduction in the 
concentrations of Aβ42 found in DRMs and a corresponding increase in DSMs (Figure 4E). This effect of glimepiride 
was blocked by inhibiting endogenous GPI-PLCs with the inclusion of p-CMPS. 
 
3.5. Aβ binds to soluble PrPC – Treatment of neurons with glimepiride causes the release of soluble PrPC into culture 
supernatants (Bate et al., 2009). The soluble PrPC in these supernatants was collected using an immunoaffinity column 
followed by low pressure reverse phase chromatography using C18 columns. PrPC eluted from C18 columns in 
concentrations of propanol between 60 and 75% whereas the soluble PrPC eluted at lower concentrations of propanol 
(Figure 5A). PrPC and soluble PrPC had different migration patterns in HPTLC consistent with a significant change in 
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hydrophobicity (Figure 5B). Since changes in the GPI anchor can alter the structure of some proteins (Barboni et al., 
1995) we tested whether Aβ bound to soluble PrPC.  PrPC and soluble PrPC were immobilised on ELISA plates and 
incubated with brain extract. Aβ bound to both PrPC and soluble PrPC, but not to soluble Thy-1, a GPI-anchored 
protein used as a control (Figure 5C).  Aβ did not bind to soluble PrPC preparations from which PrPC had been 
immunodepleted (Figure 5D) indicating that Aβ was binding to soluble PrPC and not a contaminant.  
 
3.6. Soluble PrPC blocked Aβ-induced synapse damage - The concept that disease-relevant conformations of Aβ 
may constitute only a small proportion of total Aβ (Glabe, 2008) raises the possibility that soluble PrPC might bind to 
the non-toxic forms of Aβ rather than toxic Aβ. This hypothesis was tested by examining the effects of soluble PrPC 
upon Aβ-induced synapse damage. First, Aβ was mixed with supernatants from glimepiride-treated neurons that 
contained soluble PrPC. The presence of this supernatant reduced the Aβ-induced synapse damage (Figure 6A & B). 
Supernatants from which soluble PrPC had been removed by immunodepletion did not block Aβ-induced synapse 
damage indicating that the protective component of the supernatant was soluble PrPC. To confirm the role of soluble 
PrPC as an inhibitor of Aβ-induced synapse damage soluble PrPC was isolated on C18 columns. The Aβ-induced 
synapse damage was reduced by the addition of 10 nM soluble PrPC but was not affected by 10 nM soluble Thy-1 
(Figure 6C).  To ensure that the effects of soluble PrPC were not mediated by a direct effect upon neurons, neurons 
were pre-treated with 10 nM soluble PrPC for 1 hour. They were then washed 3 times and incubated with Aβ. Under 
these conditions the soluble PrPC did not affect Aβ-induced synapse damage (Figure 6D) thus confirming that toxic 
conformations of Aβ bound to soluble PrPC.  To determine efficacy, serial dilutions of soluble PrPC were incubated 
with 500 pM Aβ42. Soluble PrPC, but not soluble Thy-1, protected neurons against Aβ-induced synapse damage in a 
dose-dependent manner (Figure 6E). The neuroprotective effect of soluble PrPC was stimulus specific as the presence 
of 10 nM soluble PrPC did not affect PLAP-induced synapse damage (Figure 6F).  
 
3.7. Glimepiride reduced Aβ-induced activation of cPLA2 in synapses - Several studies suggest that aberrant 
activation of cPLA2 is involved in Aβ-induced synapse damage. For example, Aβ peptides activate PLA2 (Shelat et 
al., 2008; Zhu et al., 2006) and inhibition of cPLA2 prevented Aβ-induced synapse damage in vitro (Bate et al., 2010) 
and in vivo (Desbene et al., 2012). Here we show that the addition of brain extract increased the amounts of activated 
cPLA2 in synapses (Figure 7A). Immunodepletion studies showed that Aβ was responsible for the activation of 
synaptic cPLA2. Pre-treatment of synaptosomes with 5 µM glimepiride, but not glipizide, reduced the Aβ-induced 
activation of cPLA2 (Figure 7B). The effects of glimepiride upon the activation of cPLA2 in synaptosomes were 
stimulus specific as it did not affect the activation of cPLA2 by PLAP (Figure 7C) indicating that glimepiride did not 
directly inhibit cPLA2. The presence of soluble PrPC did not activate synaptic cPLA2 but pre-treatment with 10 nM 
soluble PrPC significantly reduced the Aβ-induced activation of cPLA2 (Figure 7D).  
 
Upon activation, cPLA2 translocate to specific intracellular membranes utilizing an N-terminal, calcium-dependent 
lipid binding domain (Nalefski et al., 1994). Isolation of DRMs (lipid rafts) was used to quantify the change in synaptic 
location of cPLA2 in response to Aβ. In control synaptosomes less than 20% of cPLA2 was found within DRMs. The 
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addition of 1 nM Aβ42 significantly increased the amounts of cPLA2 found in DRMs in control synaptosomes. Pre-
treatment of synaptosomes with glimepiride significantly reduced the Aβ-induced translocation of cPLA2 into DRMs 
(Figure 7E). The activation of cPLA2 is the first step in the production of prostaglandins (PG) including PGE2 which 
causes synapse damage in cultured neurons (Bate et al., 2010). Here we show that pre-treatment of synaptosomes with 
5 μM glimepiride reduced Aβ-induced PGE2 production, but had no effect upon PLAP-induced PGE2 production 
(Figure 7F).  
 
3.8. Glimepiride reduced the Aβ-induced increase in cholesterol in synapses - Our finding that the addition of 
brain extracts significantly increased the concentrations of cholesterol within synaptosomes (Figure 8A) is consistent 
with reports that increased cholesterol was found in Aβ positive synapses in the cortex of AD brains (Gylys et al., 
2007). The concentrations of cholesterol in synaptosomes were not affected by the addition of Aβ-depleted brain 
extract indicating that Aβ was the molecule causing the increase in cholesterol. There was a significant correlation 
between cholesterol concentrations and activated cPLA2 in synaptosomes incubated with Aβ42 (1 to .125 nM), 
Pearson’s coefficient=0.734, P<0.01 (Figure 8B). Pre-treatment with glimepiride or PI-PLC blocked the Aβ-induced 
increase in cholesterol in synaptosomes (Figure 8C). The addition of 200 µM p-CMPS reversed the effect of 5 μM 
glimepiride upon the Aβ-induced increase in synaptic cholesterol (Figure 8D). Pre-treatment of Aβ with supernatants 
from glimepiride-treated neurons reduced the Aβ-induced increase in cholesterol, an effect that was dependent upon 
soluble PrPC (Figure 8E). Similarly, pre-treatment of Aβ with 10 nM soluble PrPC, but not 10 nM soluble Thy-1, 
blocked the Aβ-induced increase in cholesterol in synapses (Figure 8F).  
 
4. Discussion 
 
The identification of drugs that protect neurons against Aβ-induced synapse damage is a rational strategy to reduce 
the cognitive decline that is observed in AD patients. There is increasing interest in drugs used in the clinic to treat 
other diseases, whose side effects and pharmacokinetics are well known, to be prescribed “off-label” as AD treatments, 
especially those that cross the blood-brain barrier. Here we show that glimepiride affected some of the molecular 
mechanisms by which A causes neurodegeneration in tissue culture models of AD pathogenesis. The key finding, 
that physiologically relevant concentrations glimepiride (Becker et al., 2007) protected neurons against Aβ-induced 
synapse damage, was associated with subtle membrane changes at synapses including the loss of PrPC and reduced 
Aβ-induced increases in cholesterol and activated cPLA2. 
 
Low nanomolar/picomolar concentrations of Aβ triggered the loss of synaptic proteins including synaptophysin and 
CSP from cultured cortical neurons indicating synapse degeneration. These concentrations of Aβ are similar to those 
found the brains of AD patients (Mc Donald et al., 2010; McLean et al., 1999; Wang et al., 1999). Glimepiride did not 
completely block Aβ-induced synapse damage; rather it increased the concentrations of Aβ required to cause synapse 
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damage by approximately 10 fold. Neurons treated with glimepiride were not protected against synapse damage-
induced by PLAP indicating that it affected a stimulus-selective pathway. 
 
Sulphonylureas such as glimepiride mimic the effects of insulin upon cells. Like many drugs glimepiride has a broad 
range of actions and while most of the anti-diabetic effects of glimepiride are shared by glipizide, neuroprotection was 
a glimepiride-specific effect. Since glimepiride, but not glipizide, activates an endogenous GPI-PLC (Müller et al., 
2001) we hypothesised that this was the molecular basis of the protective effects of glimepiride. This hypothesis was 
supported by two observations; firstly that neurons treated with PI-PLC were also protected against Aβ-induced 
synapse damage and secondly that the protective effect of glimepiride was reversed by a selective inhibitor of GPI-
PLC.  
 
Although glimepiride reduced the expression of PrPC (Bate et al., 2009), which acts as a receptor for Aβ42 (Lauren et 
al., 2009), similar amounts of Aβ42 bound to control and glimepiride-treated neurons or synaptosomes. Aβ42 has been 
reported to bind to multiple receptors including the amyloid precursor protein (Lorenzo et al., 2000) and α7 nicotinic 
acetylcholine and glutamate receptors (Renner et al., 2010; Wang et al., 2000) and it seems likely that Aβ42 binds to 
some of these in glimepiride-treated neurons/synaptosomes. We noted that glimepiride significantly reduced the 
amounts of Aβ42 targeted to rafts and subsequently the amounts of Aβ42 that accumulated within synapses. As Aβ42 
accumulated at synapses in Prnp knockout neurons (Bate and Williams, 2011), but not in glimepiride-treated neurons, 
we concluded that glimepiride did more than simply removing PrPC from neurons. The observation that glimepiride 
did not affect the binding of Aβ42 to isolated synaptosomes suggested that in neuronal cultures Aβ42 binds to receptors 
on the cell perikyra and subsequently traffics to synapses, a process that is inhibited by glimepiride. 
 
Both lipid rafts and Aβ-induced neurodegeneration are sensitive to cholesterol depletion suggesting that the molecular 
processes leading to neurodegeneration are generated from within cholesterol-sensitive rafts (Bate and Williams, 
2007; Wang et al., 2001; Williamson et al., 2008). Since cholesterol has an important role in the synapse, the inhibition 
of cholesterol synthesis is not a feasible approach to disrupt Aβ-induced neurodegeneration. Aβ affects cholesterol 
homeostasis (Grimm et al., 2007) and here we showed that Aβ increased the concentrations of cholesterol in 
synaptosomes; an observation that is consistent with reports of increased cholesterol found in Aβ-positive synapses in 
the cortex of AD brains (Gylys et al., 2007). Such observations are compatible with the hypothesis that in normal 
synapses Aβ creates the lipid rafts responsible for synapse degeneration. The oligomerisation of GPI-anchored 
proteins triggers raft formation and the increase in synaptic cholesterol was coincident with Aβ mediated cross-linkage 
of raft-associated PrPC (Taylor and Hooper, 2006). Our observation that glimepiride did not affect the amount of Aβ42 
that bound to synaptosomes, but blocked the Aβ-induced increase in synaptic cholesterol indicates that the presence 
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of Aβ42 per se does not increase cholesterol. We hypothesise that the binding of Aβ to receptors other than PrPC in 
glimepiride-treated synaptosomes does not trigger an increase in membrane cholesterol. 
 
Lipid rafts are thought to exist as multiple, heterogeneous sub-sets that have different protein cargos and have different 
functions (Pike, 2004). Although glimepiride reduced the amounts of PrPC in synaptosomes, it did not affect rafts 
containing Thy-1, caveolin or VAMP-1 and consequently had a more selective effect than cholesterol synthesis 
inhibitors. Thus, glimepiride appeared to selectively affect the formation of those rafts that mediate Aβ-induced 
synapse damage.  Lipid rafts are dynamic in nature and adapt readily to changes in membrane composition (Pike, 
2004). The inverse correlation between the amounts of PrPC and gangliosides in synapses suggested that PrPC may 
suppress ganglioside expression. Thus the biochemical changes induced in synapses by glimepiride may be protective 
due to the removal of PrPC, forcing Aβ to bind to alternative receptors, or by increasing gangliosides which suppress 
toxicity. 
 
Precisely how Aβ triggers synapse damage is unclear. PrPC is associated with several signaling molecules including 
tyrosine kinases (Mouillet-Richard et al., 2000) and cPLA2 (Bate and Williams, 2011). The aberrant activation of 
cPLA2 is thought to underlie the pathology of AD based on reports that Aβ42 activates cPLA2 (Shelat et al., 2008; Zhu 
et al., 2006) and that inhibition of cPLA2 reduced the Aβ-induced synapse damage in vitro (Bate et al., 2010) and in 
vivo (Desbene et al., 2012). In addition, cPLA2 inhibitors ameliorate the cognitive decline seen in a transgenic model 
of AD (Sanchez-Mejia et al., 2008). Critically the Aβ-induced activation of cPLA2 in synapses was cholesterol-
sensitive (Bate and Williams, 2007). An emerging paradigm is that of cell activation occurring as a consequence of 
multiple individual rafts coalescing to form a membrane platform capable of sustained cell activation (Pike, 2004). 
PrPC acts as a scaffold protein that organises signalling platforms (Linden et al., 2012) and  activated cPLA2 was found 
within PrPC-containing rafts (Bate and Williams, 2011). The dynamic nature of raft composition (Pike, 2004) is 
consistent with the hypothesis that critical concentrations of Aβ42 triggered the formation of a raft platform capable of 
the sustained activation of cPLA2 that leads to synapse damage. In glimepiride-treated synapses most of the cPLA2 
remained in the cytoplasm and the Aβ-induced activation of cPLA2 was reduced. Initially it was thought that the 
glimepiride-induced increase in gangliosides inhibited cPLA2 (Nakamura et al., 2010) but that this hypothesis is 
unlikely as glimepiride did not inhibit PLAP-induced activation of synaptic cPLA2. We therefore conclude that Aβ42 
binding to glimepiride-treated synaptosomes does so via receptors that do not trigger a membrane platform which 
captures and activates cPLA2. 
 
Soluble PrPC was released from glimepiride-treated neurons (Bate et al., 2009) and bound Aβ oligomers. Critically, 
supernatants from glimepiride-treated neurons blocked Aβ-induced synapse damage; an activity that was dependent 
upon PrPC. Soluble PrPC also reduced both the Aβ-induced increases in synaptic cholesterol and activation of cPLA2. 
The protective effect of soluble PrPC was stimulus specific and did not affect synapse damage induced by PLAP. 
These results suggest that should soluble PrPC be generated in the brain it may be able to neutralise the toxic Aβ 
oligomers that are responsible for synapse failure, and hence the dementia associated with AD. In this regard it is of 
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interest that in a transgenic mouse model of AD containing APPPS1+ Prnp0/0 and crossed with mice producing 
anchorless PrPC (Chesebro et al., 2005) the APPPS1-related suppression of LTP was inhibited; an effect that was  
independent of any effects upon the production of Aβ42 (Calella et al., 2010). Many GPI-anchored proteins are found 
in soluble forms and although soluble PrPC is released by platelets (Perini et al., 1996) we are not aware of studies 
demonstrating soluble PrPC within the brain. Although we did not detect soluble PrPC in mouse brain extracts 
(unpublished data) it may be possible to generate enough soluble PrPC within the brain by treatment with glimepiride 
to neutralise the soluble Aβ oligomers responsible for synapse damage. 
 
5. Conclusions  
 
We report that glimepiride protected neurons against Aβ-induced synapse damage. The protective effect of glimepiride 
was associated with multiple factors including the loss of PrPC from synapses, the production of soluble PrPC, and the 
altered distribution of cholesterol, Aβ42 and cPLA2 within cell membranes. In glimepiride-treated neurons, Aβ42 was 
not targeted to lipid rafts and did not trigger synapse damage. Furthermore, in glimepiride-treated synaptosomes Aβ 
did not increase cholesterol concentrations and failed to activate cPLA2; observations indicating that glimepiride 
targets rafts involved in Aβ-induced synapse damage. As glimepiride is already used in the clinic and can cross the 
blood-brain barrier, it could be considered as a novel adjunctive treatment that could reduce the pathogenesis of AD. 
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6. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Aβ damages synapses in cultured neurons - (A) Immunoblot showing Aβ monomers (M), dimers (D) and 
trimers (T) in brain extract (1) and Aβ-depleted brain extrtact (2). (B) Immunoblots showing the amounts of synapsin-
1, VAMP-1, CSP, synaptophysin and caveolin in neurons incubated with brain extract as shown. The amounts of 
synaptophysin (D) and CSP (E) in neurons incubated with brain extract (●), Aβ-depleted brain extract () or mock-
depleted brain extract (○). Values are means ± SD from triplicate experiments performed 3 times (n=9).  
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Figure 2. Glimepiride protected neurons against Aβ-induced synapse damage - The amounts of synaptophysin 
(A) and CSP (B) in neurons pre-treated with control medium (●), 5 µM glimepiride (○) or 5 µM glipizide (■) and 
incubated with Aβ42 as shown. Values are means ± SD from triplicate experiments performed 3 times (n=9). Values 
are means ± SD from triplicate experiments performed 3 times (n=9). (C) The amounts of synaptophysin in neurons 
pre-treated with glimepiride (■) or glipizide (□) as shown and incubated with 2 nM Aβ42. Values are means ± SD from 
triplicate experiments performed 3 times, n=9. *=synaptophysin significantly higher than control neurons incubated 
with Aβ, P<0.05. (D) The amounts of synaptophysin in neurons pre-treated with a control medium (●) or 5 µM 
glimepiride (○) and washed. Washed neurons were then incubated with Aβ42 as shown. Values are means ± SD from 
triplicate experiments performed 4 times (n=12).  The amounts of synaptophysin (E) and CSP (F) in neurons pre-
treated with control medium (●), 5 µM glimepiride (○) or 5 µM glipizide (■) and incubated with PLAP. Values are 
means ± SD from triplicate experiments performed 3 times (n=9).   
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Figure 3. Digestion with PI-PLC protected neurons against Aβ-induced synapse damage - (A) The amounts of 
synaptophysin (A) and CSP (B) in neurons pre-treated with control medium (●), 0.2 units/ml PI-PLC (○) or heat-
denatured PI-PLC (□) and incubated with Aβ42 as shown. Values are means ± SD from triplicate experiments 
performed 3 times (n=9). The amounts of synaptophysin (C) and CSP (D) in neurons pre-treated with a control medium 
(●), 5 μM glimepiride (○), 200 μM p-CMPS (■) or a combination of 5 µM glimepiride and 200 μM pCMPS (□) and 
incubated with Aβ42 as shown. Values are means ± SD from triplicate experiments performed 3 times (n=9).  
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Figure 4. Glimepiride altered the composition of 
synapses – (A) The concentrations of PrPC in synaptosomes derived from neurons treated for 1 hour with glimepiride 
(□) or glipizide (■) as shown. Values are means ± SD from triplicate experiments performed 3 times, n=9. (B) 
Immunoblots showing the amounts of PrPC, Thy-1, caveolin and VAMP-1 in synaptosomes incubated with control 
medium (1) or 5 μM glimepiride (2) for 1 hour. (C) Neurons were treated with 5 μM glimepiride for 1 hour and 
synaptosomes prepared. Butanol extracts were separated on HPTLC plates and sialylated gangliosides detected using 
biotinylated S. nigra. (D) There was a significant inverse correlation between amounts of PrPC and sialylated 
gangliosides in synaptosomes prepared from neurons treated for 1 hour with glimepiride (5 µM to 0.625 µM), 
Pearson’s coefficient = -0.801, P<0.01. (E) Synaptosomes pre-treated with control medium, 5 μM glimepiride or 5 
μM glimepiride and 200 μM pCMPS were incubated with 1 nM Aβ42 for 1 hour and the amounts of Aβ42 in DRMs 
(rafts) (□) and DSM (■) measured. Values are means ± SD from triplicate experiments performed 3 times, n=9. *=Aβ42 
significantly lower than in DRMs from control synaptosomes, P<0.05.  
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Figure 5 – Glimepiride generates soluble PrPC that binds Aβ – (A) The amounts/concentrations of PrPC (●) or 
soluble PrPC (○) in fractions eluted from C18 columns under a gradient of propanol and water. Values are means of 
duplicates. (B) PrPC (1) and soluble PrPC (2) separated on silica gel 60 HPTLC plates. (C) The amounts of Aβ bound 
to immunoplates coated with 50 nM PrPC (●), 50 nM soluble PrPC (○) or 50 nM soluble Thy-1 (□) and incubated with 
brain extract as shown. Values are means (% maximum OD) ± SD from triplicate experiments performed 4 times 
(n=12). (D) The amounts of Aβ bound to immunoplates coated with a preparation containing 50 nM soluble PrPC (●) 
or the same soluble PrPC preparation that had been immunodepleted of PrPC (○) and incubated with brain extract as 
shown. Values are mean Aβ (% maximum OD) ± SD from triplicate experiments performed 4 times (n=12). 
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Figure 6 - Soluble PrPC protected neurons against Aβ-induced synapse damage – The amounts of synaptophysin 
(A) and CSP (B) in neurons incubated with Aβ pre-treated with control medium (●), supernatants from glimepiride-
treated neurons (○) or the same supernatants that had been PrPC-depleted (■). Values are means ± SD from triplicate 
experiments performed 4 times, n=12. (C) The amounts of synaptophysin in neurons incubated Aβ pre-treated with 
control medium (●), 10 nM soluble PrPC (○) or 10 nM soluble Thy-1 (■). Values are means ± SD from triplicate 
experiments performed 4 times, n=12. (D) The amounts of synaptophysin in neurons pre-treated with control medium 
(●) or 10 nM soluble PrPC (○), washed 3 times and incubated with Aβ42 as shown. Values are means ± SD from 
triplicate experiments performed 4 times, n=12. (E) The amounts of synaptophysin in neurons incubated with 4 nM 
Aβ42 that had been pre-treated with soluble PrPC (●) or soluble Thy-1 (■) as shown. Values are means ± SD from 
triplicate experiments performed 4 times, n=12. (F) The amounts of synaptophysin in neurons incubated with PLAP 
pre-treated with control medium (●) or 10 nM soluble PrPC (○). Values are means ± SD, from triplicate experiments 
performed 3 times, n=9. 
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Figure 7. Glimepiride reduced the activation of cPLA2 by Aβ – (A) The amounts of activated cPLA2 in 
synaptosomes incubated with control medium (□), brain extract (■), Aβ-depleted brain extract (striped bar) or mock-
depleted brain extract (hatched bar) as shown. Values are means ± SD from triplicate experiments repeated 3 times, 
n=9. (B) The amounts of activated cPLA2 in synaptosomes pre-treated control medium (●), 5 µM glimepiride (○) or 
5 µM glipizide (■) and incubated with Aβ42 as shown. Values are means ± SD from triplicate experiments repeated 3 
times, n=9. (C) The amounts of activated cPLA2 in synaptosomes pre-treated with control medium (●), 5 µM 
glimepiride (○) or 5 µM glipizide (■) and incubated with PLAP as shown. Values are means ± SD from triplicate 
experiments repeated 3 times, n=9. (D) The amounts of activated cPLA2 in synaptosomes incubated with Aβ42 pre-
treated with control medium (○), 10 nM soluble PrPC (●) or 10 nM soluble Thy-1 (□). Values are means ± SD from 
triplicate experiments performed 4 times (n=12). (E) The amounts of cPLA2 within lipid rafts (DRMs) from 
synaptosomes pre-treated with control medium (■) or 5 µM glimepiride (□) and incubated with 1 nM Aβ42. Values 
are means ± SD from triplicate experiments repeated 3 times, n=9. *=significantly less cPLA2 in lipid rafts than in 
control synaptosomes incubated with Aβ, P<0.05. (F) The concentrations of PGE2 produced by synaptosomes pre-
treated with control medium (■), 5 μM glimepiride (□) or 5 μM glipizide (striped bar) and incubated with Aβ or PLAP. 
Values are means ± SD from triplicate experiments performed 2 times, (n=6). *=PGE2 significantly less than control 
synaptosomes incubated with peptide. 
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Figure 8. Glimepiride reduces the Aβ induced 
increase in synaptic cholesterol - (A) The concentrations of cholesterol in synaptosomes incubated with control 
medium (□), brain extract (■), Aβ-depleted brain extract (striped bar) or mock-depleted brain extract (hatched bar). 
Values are means ± SD from quadruplicate experiments performed twice (n=8). *=cholesterol significantly higher 
than in control synaptosomes, P<0.05. (B) There was a significant correlation between the concentrations of 
cholesterol and amounts of activated cPLA2 in synaptosomes incubated for 1 hour with Aβ42 (1 to .125 nM), Pearson’s 
coefficient=0.734, P<0.01. (C) The concentrations of cholesterol in synaptosomes pre-treated with control medium, 5 
µM glimepiride, 5 μM glipizide or 0.2 units/ml PI-PLC and incubated with control medium (□) or 1 nM Aβ42 (■). 
Values are means ± SD from triplicate experiments performed 3 times (n=9). *=cholesterol significantly lower than 
synaptosomes treated with Aβ, P<0.05. (D) The concentrations of cholesterol in synaptosomes pre-treated with control 
medium, 5 µM glimepiride, 200 μM pCMPS or glimepiride and pCMPS and incubated with control medium (□) or 1 
nM Aβ42 (■). Values are means ± SD from triplicate experiments performed 3 times (n=9). *=cholesterol significantly 
lower than control synaptosomes incubated with Aβ, P<0.05.  (E) The concentrations of cholesterol in synaptosomes 
incubated with brain extract (■), brain extract mixed with the supernatant from glimepiride-treated neurons (striped 
bar) or brain extract mixed with the same supernatant immunodepleted of PrPC (hatched bar). Values are means ± SD 
from triplicate experiments performed 3 times (n=9). *=cholesterol significantly lower than control synaptosomes 
treated with brain extract, P<0.05. (F) The concentrations of cholesterol in synaptosomes incubated with brain extract 
23 
 
(■) or control medium (□) mixed with control medium, 10 nM soluble PrPC or 10 nM soluble Thy-1 (striped bars). 
Values are means ± SD from triplicate experiments performed 4 times (n=12). *=cholesterol significantly lower than 
control synaptosomes treated with brain extract, P<0.05. 
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